Molecular Diagnostics News and Research

RSS

NanoString's miRGE Assay now available for use in nCounter Analysis System

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the availability of the nCounter miRGE Assay for use on its nCounter Analysis System.

From NanoString Technologies 22 Sep 2011

OvaGene's new molecular diagnostics laboratory receives CLIA-certification

OvaGene Oncology Inc., a molecular diagnostics company specializing in the development and commercialization of personalized gene-based diagnostics for gynecologic cancer, announced today that the company has received Clinical Laboratory Improvement Act (CLIA) certification for their newly constructed state-of-the-art molecular diagnostics laboratory.

20 Sep 2011

Hologic to showcase automated systems for cervical cancer screening at IPV, Berlin

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, will focus on two new, ready-to-market automated options for cervical cancer screening at the International Papillomavirus Conference & Clinical Workshop (IPV) September 17th through 22nd in Berlin, Germany.

From Hologic, Inc. 17 Sep 2011

AmerisourceBergen completes acquisition of Premier Source

AmerisourceBergen Corporation today announced that it has completed the acquisition of Premier Source, a privately held company that provides consulting and reimbursement services to medical device, pharmaceutical, molecular diagnostic, and biotechnology manufacturers, as well as other health services companies.

2 Sep 2011

HTG announces availability of qDiscovery miRNA WTA Version 16

HTG Molecular Diagnostics today announced the availability of the qDiscovery miRNA Whole Transcriptome Array (WTA) Version 16, a complete solution for microRNA (miRNA) analysis on any sample type or size.

30 Aug 2011

QIAGEN acquires Cellestis

QIAGEN N.V. today announced that its acquisition of all the ordinary shares in Cellestis Limited by a way of a scheme of arrangement has been implemented.

From QIAGEN Manchester Limited 29 Aug 2011

FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

Abbott today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer.

29 Aug 2011

MDxHealth first half 2011 commercial revenues increase 19%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today its 2011 half-year results.

25 Aug 2011

New advances in genomics, molecular diagnostics to be showcased at CAP 2011 meeting

The latest developments in molecular diagnostics, personalized medicine, and genetics testing will be featured topics when more than 1,000 pathologists gather at the Gaylord Texan on September 11 – 14 for the annual scientific meeting of the College of American Pathologists.

24 Aug 2011

Health Canada grants medical device licence to Gen-Probe's PANTHER system

Gen-Probe Incorporated announced today that Health Canada has granted the Company a medical device license for the PANTHER system, a fully automated and integrated molecular testing system designed with the flexibility to handle a wide range of testing needs.

23 Aug 2011

LifeCodexx, Sequenom partner to commercialize prenatal lab testing services in Europe

Sequenom, Inc., a life sciences company providing innovative genetic analysis solutions, today announced it has partnered with LifeCodexx AG, a company focused on the development of clinically validated Next Generation Molecular Diagnostics, for the commercialization of prenatal laboratory testing services in Europe.

11 Aug 2011

TrovaGene regains ownership of worldwide rights to transrenal technology

TrovaGene, Inc., a developer of transrenal molecular diagnostics, confirmed today that it regained ownership of its worldwide rights and control over its patent estate for transrenal technology for non-invasive prenatal applications and cancer through the termination of a license agreement between TrovaGene and Sequenom, Inc.

10 Aug 2011

NanoString launches nCounter Rat miRNA Expression Assay Kit

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the availability of the nCounter Rat miRNA Expression Assay Kit for use on its nCounter Analysis System.

From NanoString Technologies 9 Aug 2011

Researchers use SNAP technology to assess fetal gene expression in amniotic fluid

Researchers have demonstrated the feasibility of focused fetal gene expression analysis of target genes found in amniotic fluid using Standardized NanoArray PCR (SNAP) technology.

8 Aug 2011

New polymer effectively captures nicotine molecules and analogues

Newly synthesized polymer, fitted with molecular pincers of carefully tailored structure, effectively captures nicotine molecules and its analogues.

5 Aug 2011

Akonni to develop closed amplicon RT-PCR microarray for virus detection in CSF

Akonni Biosystems, a molecular diagnostics company that develops novel nucleic acid extraction and microarray-based testing systems designed to rapidly and economically analyze biological samples, today announced receipt of a $300K grant from the National Institutes of Health.

5 Aug 2011

NanoString to begin clinical development program for Breast Cancer Intrinsic Subtyping Assay

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it is initiating the first in a series of studies to evaluate the clinical utility of the NanoString Breast Cancer Intrinsic Subtyping Assay.

From NanoString Technologies 4 Aug 2011

USPTO issues notice of allowance for Vermillion's PAD biomarker patent

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent entitled "Beta-2 microglobulin as a Biomarker for Peripheral Artery Disease."

3 Aug 2011

NanoString introduces new assay for leukemia fusion gene analysis

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the availability of a comprehensive multiplexed assay for the simple and cost-effective analysis of fusion genes linked to leukemia.

From NanoString Technologies 29 Jul 2011

Randox win Premier Healthcare Alliance contract for Quality Control

Randox Laboratories Ltd is proud to announce that in April 2011 we signed a multi-year agreement with the Premier Healthcare Alliance for the supply of Acusera Quality Control (QC) materials. The agreement will provide the 90,000 plus Premier members with access to our extensive range of quality control products and the benefits they offer clinical laboratories. When asked about the new agreement Laura Coyle Randox Business Manager for the USA revealed that ‘We look forward to strengthening our relationship with Premier and providing added value to their members’.

From Randox Laboratories Ltd. 21 Jul 2011